MIRM Mirum Pharmaceuticals, Inc. Common Stock
XNAS
92.17
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MIRM
$92.17
—
What changed
Recent filings, trades and movesKey stats
$92.17
- 52-Week Range
- $63.23 – $130.00
- YTD
- +18.07%
- IV Rank (30D)
- 34.86
- Straddle Price
- $11.43
- P/C Vol Ratio
- 0.98
- Market Cap
- $6.1B
- Open
- $95.10
- Day Range
- $91.53 – $95.10
- Volume
- 335,409
- Prev Close
- $93.72
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.75 |
| Cost of Equity (CAPM) | 8.63% (VRP-adj) |
| WACC | 8.33% |
| Volatility Risk Premium | +26.7pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +24.7% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | 1668.1% |
| Book / Price | -0.9% |
| Gross Margin (TTM) | 81.7% |
| FCF Margin (TTM) | -40.8% |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $89.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $85.27 |
| Bollinger Width / SMA20 | 21.6% (drives anchor stability) |
| Net Debt | $0.5B |
| Market Cap | $6B |
Peers used for multiples: BLLN, COGT, CORT, CYTK, GH, SYRE, TVTX, UTHR
60-Day Conviction
67%
20-Day Fair Value
≈ by Dec 8, 2026
$93.14
α +0.6%
rank 35%
conviction
45%
40-Day Fair Value
≈ by Jan 6, 2027
$94.85
α +2.5%
rank 46%
conviction
72%
60-Day Fair Value
≈ by Feb 4, 2027
$95.24
α +2.9%
rank 52%
conviction
67%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 47.8× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 67.2× · 3 peers |
| Peer P/B | n/a | 0% | median 9.5× · 6 peers |
| Peer P/S | $120.37 | 14% | median 10.8× · 6 peers |
| Market Anchor (SMA50) | $89.29 | 40% | stability 42% (BB-width) |
| Options Expected (B-L 30d) | $92.33 | 45% | 19 strikes · skew +0.44 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $6.1B
- Employees
- 433
- List Date
- 2019-07-18
- CIK
- 0001759425
- Last Earnings
- Nov 3 after close · +11.4% vs ±13.2% expected
- Headquarters
- Foster City, CA
- Homepage
- https://www.mirumpharma.com
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -0.17% | 16.44% | 21.78% | -11.86% | 16.27% | 32.21% | 12.45% |
| Feb | -3.22% | 25.07% | -1.55% | 7.97% | -2.10% | -11.09% | 2.51% |
| Mar | 7.25% | 3.19% | 1.35% | -14.18% | -2.04% | 2.54% | -0.31% |
| Apr | -5.15% | 2.41% | 7.40% | -1.34% | -1.34% | 2.84% | 0.80% |
| May | -16.42% | -3.98% | -2.82% | -6.57% | 2.40% | 5.15% | -3.71% |
| Jun | 3.84% | -18.17% | -0.92% | 34.87% | 10.70% | 21.53% | 8.64% |
| Jul | -18.04% | 25.63% | 0.43% | 18.71% | 6.80% | -11.63% | 3.65% |
| Aug | 9.21% | 8.14% | 5.85% | 7.43% | 42.00% | -6.25% | 11.06% |
| Sep | 23.11% | -17.28% | 19.52% | -5.59% | -1.39% | -13.08% | 0.88% |
| Oct | -17.93% | 4.30% | -6.38% | -4.14% | -0.48% | 1.29% | -3.89% |
| Nov | -12.32% | -19.23% | 12.84% | 14.41% | 3.11% | 7.78%* | 1.10% |
| Dec | 15.92% | 6.67% | -7.75% | -10.52% | 12.83% | -- | 3.43% |
| Total | -21.59% | 22.12% | 55.59% | 19.97% | 115.93% | 24.53% | 36.09% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $85.58
SMA 50: $89.18
SMA 200: $98.52
Current: $92.29
EMA 12: $89.23
EMA 26: $87.81
MACD: 1.4205 | Signal: 1.5169
BEARISH
ADX (14): 24.83
WEAK TREND
+DI: 27.79
−DI: 13.67
Momentum Oscillators
RSI (14): 58.02
NEUTRAL
Stoch %K: 69.10
Stoch %D: 77.89
Williams %R: -35.66
Volume & Volatility
BB Upper: $95.27
BB Lower: $75.90
NEUTRAL
OBV: 43,240,553
Vol SMA 20: 638,683
Vol ROC: -23.87%
ATR: $4.30
True Range: $3.57
HV 20: 59.4%
HV 30: 53.1%
HV 60: 44.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before MIRM’s Nov 3 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a consolidation phase with potential for a breakout or breakdown.
- Recent news sentiment is generally neutral, with some positive and negative headlines that may not have significant impact on the stock.
Primary Risks:
- Risk of a technical correction due to overbought conditions in RSI and Stochastic %K.
- Volatility has been moderate, but IV rank suggests low volatility relative to historical norms.
Investment Thesis: MIRM's recent performance is characterized by consolidation, with potential for a breakout or breakdown. The stock's moderate volatility and relatively low IV rank suggest that it may not be overreacting to recent news headlines. However, the risk of a technical correction remains due to overbought conditions in RSI and Stochastic %K.
Recent News Sentiment Impact: The recent news headlines are generally neutral, with no significant impact on the stock's price movement. The only potential catalyst is the upcoming earnings report, which could have a material impact on the stock's price.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Consolidation
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Uptrend
Support/Resistance Levels: The key levels to monitor are:
- Upper Bollinger Band: $125.81
- Middle Bollinger Band: $111.73
- Lower Bollinger Band: $97.65
- Recent highs: $114.30, $116.20
Momentum Signals:
- RSI interpretation: Neutral (35.46)
- MACD signal: Bearish (-3.60 / -2.15 / -1.45)
- Bollinger Bands position: Squeeze
Volume Analysis: The volume has been generally trending upward, with some consolidation in the past few weeks.
News & Sentiment Analysis
Recent Headlines Summary:
- Neutral headlines dominated recent news, with no significant impact on the stock's price movement.
- The only potential catalyst is the upcoming earnings report.
Sentiment Assessment: Neutral sentiment dominates, with no strong positive or negative bias.
Catalyst Identification: The upcoming earnings report could be a key catalyst for the stock's price movement.
Market Narrative: The recent news headlines are generally neutral and do not have a significant impact on the stock's price. The market narrative is one of consolidation, with potential for a breakout or breakdown.
Risk & Volatility Assessment
Risk Interpretation: Moderate risk relative to market (beta: 0.89).
Volatility Regime: Current volatility is moderate, but IV rank suggests low volatility relative to historical norms.
Options Market Signals: IV Rank: 1.0% (Low - shows if volatility is historically high/low) Current IV: 53.9% Expected Move: $10.50 (39 DTE), 7-DTE: $6.22 Volume Flow: 46 calls vs 7 puts Open Interest: 43 calls vs 3 puts Put/Call Volume Ratio: 0.15 (Bullish sentiment) Put/Call OI Ratio: 0.07
Downside Protection: The lower Bollinger Band ($97.65) provides support for the stock's price.
Market Context & Positioning
Sector Performance: MIRM is a biotech stock, which has generally been performing well in recent months.
Institutional Activity: Volume patterns suggest institutional interest in the stock.
Correlation Analysis: The stock is moderately correlated with the market (R-squared: 0.25).
Relative Valuation: MIRM is trading within its historical range, with no significant deviations from its mean price level.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $125.81
- Middle Bollinger Band: $111.73
- Lower Bollinger Band: $97.65
Breakout/Breakdown Levels:
- Recent highs: $114.30, $116.20
- Recent lows: $94.50, $96.20
Time-Sensitive Catalysts: The upcoming earnings report could be a key catalyst for the stock's price movement.
Risk Management: Stop-loss levels should be set at the lower Bollinger Band ($97.65) to manage potential downside risk.
Generated
News
All MIRM news →
Strong sales lift guidance as Mirum eyes cash-flow positive status.
Showing 1–10 of 11
Page 1 of 2
Earnings History
19 of 19 under expected move
Avg Expected Move
11.59%
Avg Actual Move
2.84%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-11-15 | Pre-Market | 3.78% | 2.46% | 0.65x | Within |
| 2022-03-09 | Pre-Market | 11.56% | 7.55% | 0.65x | Within |
| 2023-03-08 | Pre-Market | 7.36% | 0.13% | 0.02x | Within |
| 2023-05-04 | Pre-Market | 12.94% | 2.59% | 0.20x | Within |
| 2023-08-03 | Pre-Market | 10.27% | 0.16% | 0.02x | Within |
| 2023-11-02 | Pre-Market | 15.83% | 0.11% | 0.01x | Within |
| 2024-01-08 | Pre-Market | 11.72% | 1.18% | 0.10x | Within |
| 2024-02-28 | Pre-Market | 15.64% | 2.43% | 0.16x | Within |
| 2024-05-08 | Pre-Market | 14.59% | 3.36% | 0.23x | Within |
| 2024-08-07 | Pre-Market | 14.11% | 0.49% | 0.03x | Within |
| 2024-11-12 | After-Close | 12.54% | 3.88% | 0.31x | Within |
| 2025-02-26 | After-Close | 10.34% | 7.02% | 0.68x | Within |
| 2025-05-07 | Pre-Market | 9.09% | 0.54% | 0.06x | Within |
| 2025-08-06 | Pre-Market | 12.54% | 2.99% | 0.24x | Within |
| 2025-11-04 | After-Close | 9.44% | 1.24% | 0.13x | Within |
| 2026-02-25 | Pre-Market | 11.03% | 1.06% | 0.10x | Within |
| 2026-05-06 | Pre-Market | 13.33% | 4.04% | 0.30x | Within |
| 2026-08-05 | Pre-Market | 10.83% | 1.40% | 0.13x | Within |
| 2026-11-03 | After-Close | 13.19% | 11.42% | 0.87x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MIRM Options Activity & IV Rank
MIRM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 51.4%
7-DTE IV: 70.4%
Expected Move: $11.43
7-DTE Move: $8.55
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 453
Put Volume: 446
P/C Volume: 0.985
NEUTRAL
Call OI: 2,332
Put OI: 1,221
P/C OI: 0.524
Total OI: 3,553
ATM Options Pricing
ATM Call: $7.05
ATM Put: $4.38
Call %: 7.6%
Put %: 4.7%
Chain Summary
Chain Volume: 899
Chain OI: 3,553
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 26th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
26%
vs own history
GEX tilt
+0.18
OI-weighted, today
Vanna tilt
+0.82
δ-sensitivity to IV
Charm tilt
-0.78
δ-decay vs time
Vanna tilt +0.82: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.78: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 20 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)33.1MediumNov 9
IV Rank (30 DTE)34.9MediumNov 9
Straddle Price (30 DTE)$11.43Nov 9
Beta Analysis
Risk Metrics
Beta: 1.0809
Alpha: 29.13%
Correlation: 0.3047
R-Squared: 9.3%
Stock Volatility: 48.8%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
MIRM Institutional Ownership (13F)
Filings for 2026-06-30 · 117 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 58,364,618 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$12.42M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $7.90M | 63.64% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $2.52M | 20.27% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.07M | 8.58% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $620.47K | 5.00% | 2026-06-30 |
| 5 | Point72 Asset Management, L.P. | $234.14K | 1.89% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $76.93K | 0.62% | 2026-09-30 |
6 filers$6.13M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.51M | 57.27% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $901.44K | 14.70% | 2026-06-30 |
| 3 | Point72 Asset Management, L.P. | $772.66K | 12.60% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $503.40K | 8.21% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $384.66K | 6.27% | 2026-09-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $58.53K | 0.95% | 2026-06-30 |
MIRM Insider Trading (Form 4)
Latest: 2026-11-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-04 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Mixed Exer +20,000 · Sell −20,000 |
— | $46.47 | -$1.74M | EDGAR |
| 2026-10-19 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Exer (M) | +16,112 | $19.24 | $310.0K | EDGAR |
| 2026-10-14 | Robert Paul Myers | Chief Medical Officer | Grant (A) | +65,000 RSU | — | EDGAR | |
| 2026-10-06 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Exer (M) | +12,197 | $17.31 | $211.2K | EDGAR |
| 2026-09-15 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Mixed Exer +18,333 · Sell −9,943 |
+8,390 | $98.37 | -$978.1K | EDGAR |
| 2026-09-03 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell (S) | −658 | $100.00 | -$65.8K | EDGAR |
| 2026-09-03 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Mixed Exer +30,000 · Sell −30,000 |
— | $50.81 | -$2.87M | EDGAR |
| 2026-08-19 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Mixed Exer +40,000 · Sell −40,000 |
— | $53.13 | -$3.75M | EDGAR |
| 2026-08-12 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Sell (S) | −6,001 | $99.90 | -$599.5K | EDGAR |
| 2026-08-11 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Mixed Sell −20,000 · Exer +20,000 |
— | $50.93 | -$1.92M | EDGAR |
| 2026-08-05 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell (S) | −1,840 | $105.29 | -$193.7K | EDGAR |
| 2026-07-08 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Mixed Sell −20,000 · Exer +20,000 |
— | $62.60 | -$2.39M | EDGAR |
| 2026-07-08 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Sell (S) | −5,000 | $122.25 | -$611.3K | EDGAR |
| 2026-07-02 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell (S) | −2,721 | $120.00 | -$326.5K | EDGAR |
| 2026-06-18 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell (S) | −2,594 | $101.95 | -$264.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MIRM Insider Holdings
13 insiders · @ $92.29
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Patrick J Heron | Director | 464,713 | $42.89M | $20.35M | 19 | 2026-06-17 |
| 2 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | 394,137 | $36.37M | -$27.28M | 42 | 2026-11-04 |
| 3 | Michael G Grey | Director | 93,750 | $8.65M | -$12.40M | 16 | 2026-06-17 |
| 4 | Peter Radovich | PRESIDENT AND COO | 57,260 | $5.28M | -$3.99M | 31 | 2026-06-08 |
| 5 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 44,745 | $4.13M | -$3.89M | 19 | 2026-09-15 |
| 6 | Joanne Quan | CHIEF MEDICAL OFFICER | 26,151 | $2.41M | -$1.78M | 8 | 2026-03-17 |
| 7 | Jolanda Howe | SVP, GLOBAL CONTROLLER | 16,728 | $1.54M | -$9.33M | 27 | 2026-10-19 |
| 8 | Laura Brege | Director | 15,703 | $1.45M | -$1.15M | 10 | 2026-06-17 |
| 9 | Laurent Fischer | Director | 10,727 | $990.0K | $69.0K | 10 | 2026-06-17 |
| 10 | Timothy P Walbert | Director | 9,680 | $893.4K | $0 | 6 | 2026-06-17 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MIRM Board & Officers
As of SEC filings through Nov 4, 2026Directors 8
- Christopher Peetz · since Jul 17, 2019
- Laura Brege · since Jul 17, 2019
- Laurent Fischer · since Jul 17, 2019
- Michael G Grey · since Jul 17, 2019
- Patrick J Heron · since Jul 17, 2019
- William Fairey · since Aug 19, 2021
- Saira Ramasastry · on file since Jun 2022
- Lon Cardon · since Dec 19, 2022
Officers 6
- Christopher Peetz · Chief Executive Officer · listed since Jan 2024
- Peter Radovich · President and COO · listed since Jan 2024
- Eric Bjerkholt · Chief Financial Officer · since Sep 11, 2023
- Joanne Quan · Chief Medical Officer · since Jan 16, 2024
- Robert Paul Myers · Chief Medical Officer · since Sep 21, 2026
- Jolanda Howe · SVP, Global Controller · since May 1, 2023
Changes in the last 10 years (66)
| Sep 21, 2026 | Robert Paul Myers became Chief Medical Officer |
| Jan 25, 2024 | Peter Radovich listed as President and COO (previously Chief Operating Officer) in SEC filings |
| Jan 25, 2024 | Pamela Vig listed as Chief Scientific Officer (previously Head of Research & Development) in SEC filings |
| Jan 25, 2024 | Christopher Peetz listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Jan 16, 2024 | Joanne Quan became Chief Medical Officer |
| Sep 13, 2023 | Patrick J Heron no longer listed as a 10% owner in SEC filings |
| Sep 11, 2023 | Eric Bjerkholt became Chief Financial Officer |
| Jun 15, 2023 | Scott D Sandell reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Paul Edward Walker reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | New Enterprise Associates 16, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Nea 16 Gp, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | NEA Partners 16, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Mohamad Makhzoumi reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Forest Baskett reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Carmen Chang reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Anthony A. Florence Jr. reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2023 | Ali Behbahani reported in an SEC filing no longer being a 10% owner |
| May 1, 2023 | Jolanda Howe became SVP, Global Controller |
| Apr 5, 2023 | Timothy P Walbert became a director |
| Apr 5, 2023 | The company announced the departure of Timothy P Walbert from the board in an SEC filing |
| Jan 7, 2023 | The company announced the departure of Ian Clements as Chief Financial Officer in an SEC filing |
| Dec 19, 2022 | Lon Cardon became a director |
| Dec 16, 2022 | The company announced the departure of Carol L Brosgart from the board in an SEC filing |
| Jun 6, 2022 | Saira Ramasastry first on file as a director |
| May 12, 2022 | Pamela Vig listed as Head of Research & Development (previously Chief Scientific Officer) in SEC filings |
| Aug 19, 2021 | William Fairey became a director |
| Jun 4, 2021 | Carol L Brosgart became a director |
| Apr 28, 2020 | Peter Radovich became Chief Operating Officer |
| Jan 14, 2020 | Ian Clements listed as Chief Financial Officer (previously SVP Finance & Communications) in SEC filings |
| Jan 2, 2020 | Michael G Grey no longer listed as Executive Chairman in SEC filings |
| Oct 24, 2019 | Edwin Jonathan Tucker became Chief Medical Officer |
| Jul 17, 2019 | Tiba Aynechi became a director |
| Jul 17, 2019 | Takeda Pharmaceutical Co Ltd became a 10% owner |
| Jul 17, 2019 | Shire International GmbH became a 10% owner |
| Jul 17, 2019 | Scott D Sandell became a 10% owner |
| Jul 17, 2019 | Peter W. Sonsini became a 10% owner |
| Jul 17, 2019 | Peter J Barris became a 10% owner |
| Jul 17, 2019 | Paul Edward Walker became a 10% owner |
| Jul 17, 2019 | Patrick J Heron became a director |
| Jul 17, 2019 | Patrick J Heron became a 10% owner |
| Jul 17, 2019 | Pamela Vig became Chief Scientific Officer |
| Jul 17, 2019 | Novo Holdings A/S became a 10% owner |
| Jul 17, 2019 | Niall O'Donnell became a director |
| Jul 17, 2019 | New Enterprise Associates 16, L.P. became a 10% owner |
| Jul 17, 2019 | Nea 16 Gp, LLC became a 10% owner |
| Jul 17, 2019 | NEA Partners 16, L.P. became a 10% owner |
| Jul 17, 2019 | Mohamad Makhzoumi became a 10% owner |
| Jul 17, 2019 | Michael G Grey became a director |
| Jul 17, 2019 | Michael G Grey became Executive Chairman |
| Jul 17, 2019 | Laurent Fischer became a director |
| Jul 17, 2019 | Laura Brege became a director |
| Jul 17, 2019 | Lara Longpre became Chief Development Officer |
| Jul 17, 2019 | Joshua Makower became a 10% owner |
| Jul 17, 2019 | James N Topper became a 10% owner |
| Jul 17, 2019 | Ian Clements became SVP Finance & Communications |
| Jul 17, 2019 | Frazier Life Sciences IX, L.P. became a 10% owner |
| Jul 17, 2019 | Forest Baskett became a 10% owner |
| Jul 17, 2019 | Fhmls Ix, L.p. became a 10% owner |
| Jul 17, 2019 | Fhmls Ix, L.l.c. became a 10% owner |
| Jul 17, 2019 | Edward T Mathers became a director |
| Jul 17, 2019 | David M Mott became a 10% owner |
| Jul 17, 2019 | Christopher Peetz became a director |
| Jul 17, 2019 | Christopher Peetz became President and CEO |
| Jul 17, 2019 | Carmen Chang became a 10% owner |
| Jul 17, 2019 | Anthony A. Florence Jr. became a 10% owner |
| Jul 17, 2019 | Ali Behbahani became a 10% owner |
Not reported recently (17)
- Pamela Vig · Last reported as Chief Scientific Officer in an SEC filing dated Jun 25, 2024
- Lara Longpre · Last reported as Chief Development Officer in an SEC filing dated Mar 18, 2024
- Niall O'Donnell · Last reported as a director in an SEC filing dated Nov 15, 2022
- Edward T Mathers · Last reported as a director in an SEC filing dated Jun 6, 2022
- Edwin Jonathan Tucker · Last reported as Chief Medical Officer in an SEC filing dated Nov 15, 2021
- James N Topper · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Fhmls Ix, L.p. · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Frazier Life Sciences IX, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Fhmls Ix, L.l.c. · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- David M Mott · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Peter W. Sonsini · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Joshua Makower · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Peter J Barris · Last reported as a 10% owner in an SEC filing dated Jul 24, 2019
- Novo Holdings A/S · Last reported as a 10% owner in an SEC filing dated Jul 23, 2019
- Takeda Pharmaceutical Co Ltd · Last reported as a 10% owner in an SEC filing dated Jul 17, 2019
- Shire International GmbH · Last reported as a 10% owner in an SEC filing dated Jul 17, 2019
- Tiba Aynechi · Last reported as a director in an SEC filing dated Jul 17, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MIRM Proposed Insider Sales (Form 144)
Latest: 2026-11-04
? Form 144 Guide
Last 30d:
2 filings
· $3.2M notice value
· Last 90d:
6 filings
· $11.8M notice value
· 4 unique filers
· 33% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
CHRISTOPHER PEETZ (2, $4.8M) · JOLANDA MARIE HOWE (1, $4.0M) · ERIC BJERKHOLT (2, $1.6M) · Joanne Quan (1, $1.4M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-04 | CHRISTOPHER PEETZ | Officer, Director | 20,000 | $1.80M | 2026-11-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-11-04 | Joanne Quan | Former Officer | 14,684 | $1.42M | 2026-11-04 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-09-15 | ERIC BJERKHOLT | Officer | 9,943 | $978.1K | 2026-09-14 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-09-01 | CHRISTOPHER PEETZ | Officer, Director | 30,000 | $2.96M | 2026-09-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-18 | JOLANDA MARIE HOWE | Officer | 40,000 | $4.00M | 2026-08-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-11 | ERIC BJERKHOLT | Officer | 6,001 | $599.5K | 2026-08-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-08-10 | CHRISTOPHER PEETZ | Officer, Director | 20,000 | $1.98M | 2026-08-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-03 | JOLANDA MARIE HOWE | Officer | 1,840 | $193.7K | 2026-08-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-06 | CHRISTOPHER PEETZ | Officer, Director | 20,000 | $2.45M | 2026-07-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-06 | ERIC BJERKHOLT | Officer | 5,000 | $611.3K | 2026-07-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
73 ETFs hold MIRM
25 shown · $812.27M total exposure · 0.16% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $151.5M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.19% | $118.9M | $10.0B | 2026-11-05 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.15% | $115.5M | $76.6B | 2026-11-06 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.06% | $106.1M | — | 2026-09-30 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.13% | $59.1M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.06% | $53.9M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.31% | $42.1M | $13.7B | 2026-11-06 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.34% | $37.7M | $11.1B | 2026-11-06 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.13% | $23.6M | — | 2026-09-30 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.10% | $22.4M | — | 2026-08-31 |
| 11 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.19% | $12.6M | $6.6B | 2026-11-05 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.05% | $11.1M | — | 2026-09-30 |
| 13 | PSC Principal U.S. Small-Cap ETF | Nport | 0.30% | $7.1M | — | 2026-06-30 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $7.0M | $93.2B | 2026-11-06 |
| 15 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.16% | $6.6M | $4.2B | 2026-11-06 |
| 16 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.22% | $5.9M | — | 2026-06-30 |
| 17 | LFSC F/m Emerald Life Sciences Innovation ETF | Nport | 4.32% | $5.5M | — | 2026-08-31 |
| 18 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.26% | $4.4M | — | 2026-09-30 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.83% | $4.3M | — | 2026-11-06 |
| 20 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $3.4M | — | 2026-09-30 |
| 21 | ILDR First Trust Innovation Leaders ETF | First Trust | 1.06% | $3.3M | $316.1M | 2026-11-06 |
| 22 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.85% | $3.1M | — | 2026-08-31 |
| 23 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.01% | $2.9M | — | 2026-08-31 |
| 24 | RSSL Global X Russell 2000 ETF | Global X | 0.15% | $2.1M | — | 2026-11-06 |
| 25 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.05% | $2.1M | $4.0B | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-15.24
TTM Revenue
$670.78M
TTM Net Income
$-903.88M
TTM Op. Cash Flow
$-271.26M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $185.72M | $-40.77M | $-0.62 | $-4.31M |
| Q2 '26 | 2026-06-30 | $176.24M | $-67.23M | $-1.06 | $-44.25M |
| Q1 '26 | 2026-03-31 | $159.88M | $-790.15M | $-13.43 | $-228.76M |
| Q4 '25 | 2025-12-31 | $148.93M | $-5.73M | $-0.12 | $6.07M |
| Q3 '25 | 2025-09-30 | $133.01M | $2.90M | $0.05 | $39.68M |
| Q2 '25 | 2025-06-30 | $127.78M | $-5.86M | $-0.12 | $12.04M |
| Q1 '25 | 2025-03-31 | $111.58M | $-14.68M | $-0.30 | $-1.96M |
| Q4 '24 | 2024-12-31 | $99.41M | $-23.79M | $-0.49 | $-5.07M |
| Q3 '24 | 2024-09-30 | $90.38M | $-14.23M | $-0.30 | $3.98M |
| Q2 '24 | 2024-06-30 | $77.88M | $-24.64M | $-0.52 | $-3.80M |
| Q1 '24 | 2024-03-31 | $69.22M | $-25.28M | $-0.54 | $15.21M |
| Q4 '23 | 2023-12-31 | $69.55M | $-35.66M | $-0.72 | $-16.62M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
8.58
EV/EBITDA
—
EV/Sales
9.25
ROE
—
ROA
-82.3%
Div Yield
0.00%
FCF Yield
-4.29%
Debt/Equity
—
Current Ratio
—
Market Cap
$5.30B
as of 2026-11-09
MIRM vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| UTHR United Therapeutics Corp | $23.9B | 22.1 | +1.9% | +17.6% | 25 |
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +56.9% | 25 |
| SYRE Spyre Therapeutics, Inc. Common Stock | $9.9B | — | — | +256.7% | 11 |
| CORT Corcept Therapeutics Inc. | $7.9B | 59.3 | +30.0% | +97.0% | 100 |
| CYTK Cytokinetics Inc. | $7.5B | — | −21.1% | −10.1% | 53 |
| MIRM Mirum Pharmaceuticals, Inc. Common Stock | $6.1B | — | +42.2% | +18.2% | 35 |
| COGT Cogent Biosciences, Inc. Common Stock | $5.5B | — | — | −3.5% | 94 |
| BLLN BillionToOne, Inc. Class A Common Stock | $5.4B | 164.1 | — | +28.7% | 47 |
| TVTX Travere Therapeutics, Inc. Common Stock | $4.8B | — | +49.4% | +28.5% | 22 |
| Peer median | $7.7B | 59.3 | +30.0% | +28.6% | 36 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.66M
SI % of Float
12.89%
Days to Cover
7.30
Short Vol Ratio
24.8%
Free Float
51.69M
Float %
79.6%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22